Showing results (101-110 of 122) with videos related to
Sort By:
Pageof 13
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 22, 2023
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO)Caroline Wall, Hua Xiang, Ben Palmer, et al.Thrombosis and Haemostasis|December 2, 2016
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia APaul Giangrande, Tatiana Andreeva, Pratima Chowdary, et al.Journal of Thrombosis and Haemostasis : JTH|October 29, 2025
A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapyCaroline M A Mussert, Wolfgang Miesbach, Pratima Chowdary, et al.Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2021
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experienceOliver C Cohen, Michele Bertelli, Gavin Manmathan, et al.The New England Journal of Medicine|July 20, 2022
Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia BPratima Chowdary, Susan Shapiro, Mike Makris, et al.The New England Journal of Medicine|April 29, 2026
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without InhibitorsMaria Elisa Mancuso, Anthony K C Chan, Chandrakala Shanmukhaiah, et al.Blood Advances|June 24, 2026
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 studyGuy Young, Pantep Angchaisuksiri, Shashikant J Apte, et al.The Lancet. Haematology|January 30, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 studyClaude Négrier, Johnny Mahlangu, Michaela Lehle, et al.British Journal of Clinical Pharmacology|April 22, 2021
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patientsTim Preijers, Ri Liesner, Hendrika C A M Hazendonk, et al.British Journal of Clinical Pharmacology|August 11, 2023
A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia BSjoerd F Koopman, Tine M H J Goedhart, Laura H Bukkems, et al.Pageof 13